Joaquin Mateo, MD, from the Institute of Cancer Research and The Royal Marsden, London, UK speaks to us about the current state of our understanding on the optimal time to administer PARP inhibitors in prostate cancer patients, and tells us why healthcare professionals may be encouraged to utilize them as early as possible. This interview was recorded at the 2017 European Society for Medical Oncology (ESMO) conference held in Madrid, Spain.